Pegasus Biotech, a leading biotechnology contract research organization, has announced the development of BPE plasmid technology that revolutionizes the way plasmid DNA replicates. The patented origin in BPE plasmid technology remains inactive during fermentation but can be activated at high cell densities to increase replication levels significantly. This technology is unique because it does not rely on antibiotic resistance selection markers and contains minimal bacterial sequences.
BPE plasmids exhibit up to 7 times higher expression compared to traditional plasmid backbones, making them ideal for vaccine and gene-therapy product development. The transformative potential of this technology lies in its ability to meet project requirements of low cost, minimal bacterial sequences, high expression, and no antibiotic resistance selection marker.
Pegasus Biotech specializes in biopharmaceutical and vaccine development and ensures that client projects result in commercially viable products that comply with global regulations. They offer services spanning seed-to-formulation process development and associated analytical development. Their expertise in vaccine and biopharmaceutical development makes them leaders in DNA vaccine development.
For more information about Pegasus’ services, visit their website at www.pegasusbio.com. Daniel Wilson, COO of Pegasus Biotech, emphasized the transformative potential of this technology in applications where cost of goods sold (COGS) and patient safety are critical factors. For media inquiries, please contact Daniel Wilson at Pegasus Biotech Inc., 1-855-498-3398 or via email at [email protected].
